Adjuvant anastrozoleversus exemestaneversus letrozole,upfront or after 2years of tamoxifen,inendocrine-sensitivebreast cancer(FATA-GIM3) Sabino De PlacidoCiro GalloMichelino De Laurentiis2018 год

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
статья из журнала